Back to ISMICS Main Site
 


Quick Links
   Home
Loading

 



Back to 2014 Annual Meeting Display Posters


Liposomal Bupivacaine in the Management of Early Peri-operative Pain in Robotic Cardiac Surgery: Impact of a Novel Longer Acting Local Anesthetic Agent
Husam H. Balkhy1, Susan Arnsdorf2, Dorothy Krienbring2, John Urban2.
1University of Chicago Medicine & Biological Sciences, Chicago, IL, USA, 2The Wisconsin Heart Hospital, Milwaukee, WI, USA.

OBJECTIVE:
Endoscopic robotic cardiac surgery (e.g. TECAB) is the least invasive of cardiac surgeries and provides benefits over sternotomy; faster recovery, quicker pain resolution, shorter hospital stays. Patients have high expectations for significantly less pain, which is not always the case early postoperatively due to inter-costal incisions and chest tubes. We evaluated the impact of liposomal bupivacaine (LB) in the management of early postoperative pain after endoscopic procedures.
METHODS:
We compared LB to our standard of care (SOC) 0.25% bupivacaine HCL; both via local infiltration. A retrospective review was conducted involving 60 patients who underwent coronary, valve, and atrial fibrillation ablation surgeries between March 1, 2013 and June 1, 2013. Thirty patients received LB (1.3%, 266 mg in 20 mL, plus 20mL 0.9% sterile normal saline) and 30 patients received SOC bupivacaine (0.25%, 100mg in 40 mL). Data points collected included numeric rating scale pain scores, opioid consumption, and postoperative nausea and vomiting.
RESULTS:
Patient demographics between the groups were similar. There were no major morbidities in either group. Surgery time and length of stay were similar; most patients were discharged postoperative day three. Pain scores were lower in LB group compared to SOC as was opioid consumption, 112mg SOC vs. 105mg LB; no outcome reached statistical significance, however a trend in favor of LB was observed. We also noticed a trend of improved incentive spirometry volumes in LB group.
CONCLUSIONS:
This study demonstrated safety and potentially improved efficacy of liposomal bupivacaine in robotic cardiac surgery. We are embarking on a larger prospective study to ascertain the benefits of this new local anesthetic in early peri-operative pain in robotic cardiac procedures.


Download ePoster


Back to 2014 Annual Meeting Display Posters
 
© 2026 International Society for Minimally Invasive Cardiothoracic Surgery. All Rights Reserved. Read Privacy Policy.